Drug intelligence / Profile preview

abobotulinumtoxinA + brimonidine

Development stage
Unknown
Lead developer
Ipsen
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Intramuscular, Ophthalmic, Topical
01

Overview

AbobotulinumtoxinA (marketed as Dysport) is a neuro-muscular blocker and acetylcholine release inhibitor derived from the bacterium *Clostridium botulinum*. It is used to treat cervical dystonia (abnormal head position and neck pain), muscle spasms and stiffness (spasticity) in adults and children, as well as for cosmetic reduction of facial wrinkles. Its mechanism involves inhibition of synaptosomal-associated protein 25 (SNAP-25), thereby blocking acetylcholine release at neuromuscular junctions and causing temporary muscle paralysis[3][5][8]. Brimonidine is a highly selective alpha-2 adrenergic receptor agonist used primarily to lower intraocular pressure in patients with glaucoma or ocular hypertension, and also for facial erythema in rosacea. It works by decreasing aqueous humor production and increasing uveoscleral outflow in the eye[1][4]. Brimonidine’s selectivity reduces systemic side effects compared to other adrenergic agonists.

Brand names
Alphagan
Other names
botulinum toxin type Aabobotulinum toxin A
02

Targets

ADRA2A (α2A)SNAP25 (Synaptosome-associated protein 25)

Beyond the preview

Go deeper on abobotulinumtoxinA + brimonidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on abobotulinumtoxinA + brimonidine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call